

Development and optimization of erythromycin-loaded lipid-based gel by Taguchi design: *In vitro* characterization and antimicrobial evaluation

Pallavi Dhillon¹, Mohd. Aamir Mirza^{1*}, Md. Khalid Anwer², Abdullah Saud Alshetaili²,
Saad Maria Alshahrani², Zeenat Iqbal^{1*}

¹Department of Pharmaceutics, SPER, Jamia Hamdard University, New Delhi, India, ²Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, Saudi Arabia

The foremost aim of the current research was to prolong and sustain the release of erythromycin (ERY) by preparing a solid lipid nanoparticles (SLNs)-based gel formulation for the safe and effective treatment of acne. ERY-loaded SLNs were developed, and various process variables were optimized with respect to particle size, zeta potential, and entrapment efficiency using the Taguchi model. The average particle size, PDI, zeta potential, drug entrapment efficiency, and drug loading of optimized SLN (F4) were found to be 176.2 ± 1.82 nm, 0.275 ± 0.011 , -34.0 ± 0.84 , 73.56%, and 69.74% respectively. The optimized SLN (F4) was successfully incorporated into the carbopol-based hydrogel. The *in vitro* release of ERY from the SLN gel and plain gel were compared and found to be 90.94% and 87.94% respectively. *In vitro* study of ERY-loaded SLN gel showed sustained delivery of drug from formulation thus enhancing the antimicrobial activity after 30 hours when compared to ERY plain gel.

Keywords: Erythromycin. Solid lipid nanoparticles. Nanogel. Taguchi model. Characterization. Diffusion disc.

INTRODUCTION

Solid lipid nanoparticles (SLNs) offer an attractive means of drug delivery, particularly for poorly water-soluble drugs. They blend the advantages of polymeric nanoparticles (Nadkar, Lokhande, 2010), emulsions, and liposomes (Loxley, 2009; Mishra, Patel, Tiwari, 2010). SLNs consist of the drug entrapped in a biocompatible lipid core and surfactant in the outer shell, offering a good alternative to polymeric systems (Ekambaram, Sathali, Priyanka, 2012) in terms of lower toxicity (Muller, Mader, Gohla, 2000). Moreover, the production process can be modulated for desired drug release, protection of drug degradation, and avoidance of organic solvents. The aforementioned advantages make SLNs a promising carrier system for optimal drug delivery (Helgason *et al.*, 2009). ERY is a safe and effective agent for the treatment of acne. Furthermore, dibenzoyl peroxide's lipophilic

nature enhances transport through sebaceous glands, with maximum penetration through acne follicles. ERY can be bonded with the SLN surface to facilitate drug targeting of the skin strata and increase the efficiency of the acne remedy (Mehnert, Mader, 2001).

Topical ERY is used for the treatment of inflammatory acne vulgaris that occurs due to activity against propionibacterium acne (Manjunath, Enkateswarlu, 2004). It is slightly soluble in water and freely soluble in methanol. ERY base and triamcinolone acetonide are examples of topical drugs with poor dermal localization due to lipophilicity. SLNs could be suitable carriers for these drugs with a potential impact on their dissolution.

The Taguchi model has been successfully used for the optimization of process variables. The design of the experiments aims to reduce the experimental runs required for optimization. The Taguchi model design is based on a special set of orthogonal arrays to standardize fractional factorial designs. This approach reduces the size of the factorial design. An orthogonal array implies that the design is well-adjusted such that the factor levels are weighed equally. Each factor can be

*Correspondence: Z. Iqbal. Nano-formulation Research Lab, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard University, New Delhi – 110062, India. E-mail: ziqbaljh@yahoo.co.in. Mohd. Aamir Mirza. E-mail: aamir.jhu07@gmail.com, Mobile: 91-9213378765

evaluated independently of the other factors. This allows the assessment of the effect of one factor without the interference of the effects of other factors (Taguchi, 1987).

The purpose of this study to develop ERY-loaded SLNs-based gel with the potential to sustain and delay the release of the drug. The developed gel may be suitable for the treatment of acne.

MATERIAL AND METHODS

Material

Glyceryl monostearate, Polaxomer 188, stearic acid, and Compritol were obtained from HiMedia Lab, Mumbai, India. Lecithin was obtained from Spectrum Chemicals and erythromycin from Yarrow Chemicals, Mumbai, India. All the other reagents and solvents used were of analytical reagent grade.

Formulation and optimization of SLNs

Selection of method for preparation of SLNs

Three different methods were used for the preparation of ERY-loaded SLNs.

Microemulsion Technique

The lipid is melted, and a mixture of water, surfactant, and co-surfactant(s) was heated at the same temperature as the lipid. It was then added under mild stirring (1000 rpm) to the melted lipid. A transparent, thermodynamically stable system was formed, since the compounds were mixed in the correct ratio. This microemulsion was then dispersed in a cold aqueous medium (2–3 °C) under mild mechanical mixing ensuring that the small size of the particle is due to the precipitation and not mechanically induced by a stirring process (Surender, Deepika, 2016).

Solvent Emulsification/Evaporation Technique

The lipid was dissolved in a water-miscible organic solvent (methanol and chloroform, 1:1) and the drug was dispersed in the lipid solution. It was then emulsified in an aqueous phase containing the surfactant and the co-surfactant. Upon evaporation of the solvent in a Rota evaporator, a nanoparticle dispersion was formed by the precipitation of the lipid in the aqueous phase (Ahlin, Kristl, Kobar, 1998).

Solvent Emulsification Diffusion Technique

Different amounts of drugs and lipids were taken – each dissolved in a 2 mL mixture of methanol and chloroform (1:1) separately (as internal oil phase).

Powdered ERY (50 mg) was dispersed in the above solution and sonicated for 2 minutes. The resulting dispersion was poured into a solution containing 1.5% (w/v) aqueous surfactant solution (PluronicF-68) and homogenized for 30 minutes at 4000 rpm to form an o/w emulsion. After homogenization, the emulsion was poured into ice-cold water up to a volume of 50 ml and stirred for 3 hours to diffuse the organic solvent into external aqueous phase water. The dispersion was then centrifuged at 12000 rpm for 15 minutes (Sartorius FI8 K) to separate the solid lipid material containing the drug. This was then re-dispersed in a 1.5% aqueous surfactant (Pluronic F-68) solution and sonicated for 10 minutes (Surender, Deepika, 2016).

Optimization of formulation component and process variables

Screening of lipids for SLNs

A constant amount of drug (50 mg) was weighed and dispersed into the lipid solution in different ratios ranging from 1:1 to 1:10 of lipids, and the rest of the parameters were kept constant. The surfactant concentration was found to be 1% w/w. It was then homogenized for 30 minutes with a stirring time for 3 hours and sonicated for 5 minutes.

Optimization of drug lipid loading ratio

A constant amount of drug (50 mg) was weighed and dispersed into lipid in different ratios ranging from 1:1 to 1:5 of lipids and the rest of the parameters were kept constant. The surfactant concentration was 1% w/w. It was homogenized for 30 minutes with a stirring time for 3 hours and then sonicated for 5 minutes.

Optimization of surfactant concentration

On the basis of the reported literature, the concentration of surfactant was optimized for a drug lipid ratio of 1:2. The ratios used for the formulation were 0.5%, 1%, 1.5%, and 2%. The surfactant was added at the time of emulsification, and the concentration of the surfactant was optimized regarding the particle size and aggregation after 24 hours.

Optimization of stirring time

During the process of stirring, organic solvents diffuse into the aqueous phase, leading to the synthesis of SLNs. The speed and the time of stirring may influence the particle size as well as the drug entrapment. In the present study, the stirring speed was kept constant at 3000 rpm (calibrated by thread method), and the time of

stirring was optimized. Three points of time were used for the optimization – 30, 45, and 60 minutes – at a constant surfactant concentration of 2%, a drug: lipid ratio of 1:2, and a sonication time of 4 minutes.

Optimization of probe sonication

The probe sonicator (Bandelin Sonoplus, Biomate India) was used to optimize the sonication time viz 5, 10, 15, and 20 minutes with the following parameters 5×10 cycle and 50% power.

Design of experiments by the Taguchi model

This involves the factorial design for optimization of process variables (Nazzal, Khan, 2002). On the basis of the literature reported, the aforementioned series of experiments were performed to identify the controlling factor and the noise factor. There are various factors that seem to affect the formulation. An experimental design is a statistical technique used to simultaneously analyze the influence of multiple factors on the properties of the system being studied. The purpose of an experimental design is to plan and conduct experiments in order to extract the maximum amount of information from the collected data in a minimal number of experimental runs. Factorial design, based on the response surface method, is applied to design formulations. However, an increase in the number of factors significantly increases the number of experiments that need to be carried out. The Taguchi approach proposes a special set of orthogonal arrays to standardize the fractional factorial design. This approach reduces the size of the factorial design, and a study can be performed with 9 sets of experiments for a three-level, four-factor (3^4) design of experiments. The codes for all four variables at three different levels are illustrated in Table VII in the results and discussion section.

Characterization of SLNs

Measurement particle size, zeta potential, and size distribution

SLNs dispersions were diluted 50 times with the double distilled water for size determination and zeta potential measurement. Higher value of zeta potential may lead to disaggregation of particles in the absence of other complicating factors such as steric stabilizers or hydrophilic surface appendages. Zeta potential measurements allow predictions regarding the storage stability of colloidal dispersions (Yassin *et al.*, 2010; Anwer *et al.*, 2016a; Anwer *et al.*, 2016b).

In vitro drug release studies from SLNs

In vitro release studies were performed in pH 6.4 phosphate buffer using dialysis membrane (Mol. wt. 12000–14000 Dalton), and 5 mL of suspension was placed inside the dialysis tube, following which it was dipped the filled tube in buffer medium. The rpm of magnetic bead was 100 and the temperature was 37 °C. At time intervals 0, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24 hours, 1 mL aliquots were withdrawn, diluted suitably with fresh buffer solution, and analyzed for the drug content spectrophotometrically at 483.5 nm (Bhadra, Prajapati, Bhadra, 2016). The *in vitro* drug release was performed in triplicate. The concentration of ERY in test samples was calculated using a regression equation of the calibration curve.

Development of optimized SLN-loaded gel

Hydrogel base were prepared by carbopol 940. Carbopol resin were soaked in double distilled water (10% Glycerin) for 12 hours and then dispersed by agitating at approximately 1000 rpm with aid of mechanical stirrer for 10 minutes to get a smooth dispersion. Stirring was stopped and dispersion was allowed to stand so that any entrained air could escape. At this stage, optimized ERY-loaded SLN was incorporated into gel with continuous stirring for 10 minutes. Any entrapped air in the gel was allowed to escape by allowing the gels to stand overnight (Bisht *et al.*, 2017).

Evaluation of hydrogel

The developed gel was evaluated for their clarity, pH, viscosity, spreadability, extrudability, occlusion effect, and *in vitro* drug release (Bisht *et al.*, 2017).

Clarity

The clarity of developed gel formulation was determined by visual inspection under black and white background and it was graded as follows;

Turbid: +, clear: ++, very clear (glassy): +++.

pH

2.5 gm of gel was accurately weighed and dispersed in 25 ml of distilled water. The pH of dispersion was measured by digital pH meter (Systronic pH system 362).

Homogeneity

All developed gels were tested for homogeneity by visual inspection after the gels have been set in the container for their appearance and presence of any aggregate.

Spreadability

It was determined by wooden block and slide apparatus invented by Multimer *et al.* (1956). For the determination of spreadability, 1 gm of sample was applied in between two glass slide and was compressed to uniform thickness by placing some weight for 5 minutes. Weight (50gm) as added to pan. The time required to separate the two slides, i.e. the time in which the upper glass slide moves over the lower plates was taken as measure of spreadability (S). Time (T) taken to separate the slide completely from each other Viscosity measurement. The value of spreadability indicates that the gel is easily spreadable by small amount of shear.

Spreadability was calculated by using the formula:

$$S = ML/T$$

where S = Spreadability; M = Weight tide to upper slide; L = Length moved on the glass slide; T = Time.

Extrudability

The extrudability test was carried out by using Pfizer tester, 10gm of gel was filled in aluminum tube. The plunger was adjusted to hold the tube properly. The pressure of 1 Kg/gm² was applied for 30 sec. The quantity of gel extruded was weighed. The procedure was repeated at three equidistance places of the tube. Test was carried out in triplicates.

Viscosity

Viscosity of the gels was determined using a Brookfield viscometer, by using small sample adapter having spindle number SC4/13R (Middleboro, MA, USA). The gel was subjected to torque ranging from 10 to 100%. The viscosity of various formulation ERY hydrogel was measured using a Brookfield viscometer.

In vitro drug release from SLN gel

In vitro release studies were performed in phosphate buffer (pH 6.4) using dialysis membrane (Mol wt. 12000-14000 Dalton), and 0.5 gm of ERY-loaded plain gel as well as ERY SLN-loaded gel were placed inside the dialysis bag and dipped in a tube containing buffer medium. The tubes were placed in the biological shaker after setting 100 rpm and temperature 37 °C. Aliquots (1 mL) were withdrawn at time intervals (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24) and replaced by an equal volume of fresh dissolution medium. The samples were analyzed spectrophotometrically in triplicate at 483.5 nm after suitable dilution (Bhadra, Prajapati, Bhadra, 2016). The *in*

vitro release data was fitted according to different kinetic models to analyze the release behavior from SLN-loaded gel (Bisht *et al.*, 2017).

In vitro antimicrobial activity: Disk diffusion method

Disk diffusion refers to the diffusion of an antimicrobial agent of a specified concentration from disks, tablets, or strips into a solid culture medium that has been seeded with the selected inoculum isolated in a pure culture. Disk diffusion is based on the determination of an inhibition zone that is proportional to the bacterial susceptibility and the antimicrobial present in the disk. The diffusion of the antimicrobial agent into the seeded culture media results in a gradient of the antimicrobial agent. When the concentration of the antimicrobial agent becomes so diluted it can no longer inhibit the growth of the test bacterium, the zone of inhibition is demarcated. The diameter of this zone of inhibition around the antimicrobial disk is related to minimum inhibitory concentration (MIC) for that particular bacterium/antimicrobial combination. The zone of inhibition correlates inversely with the MIC of the test bacterium. Generally, the larger the zone of inhibition, the lower the concentration of antimicrobial agent required to inhibit the growth of the organisms. However, this depends on the concentration of antibiotic in the disk as well as its diffusibility.

The *in vitro* antibacterial activities of plain gel and SLN-loaded gel were performed against *S. aureus* by disc diffusion method. Under aseptic conditions, empty sterile discs were impregnated with 50 mg of ERY SLN-loaded gel as well as ERY plain gel and placed on the surface of the agar using sterile forceps. All petri dishes containing the microorganisms were sealed and incubated for 48 hours in a temperature of 37°C. After the incubation period, the diameter of the inhibition zones was observed where clear zones were seen on the agar and measured using a ruler to the nearest millimeter readings. The test was performed in triplicates, and mean values of the diameters of the inhibition zones were calculated for both samples (Balouiri, Sadiki, Ibsouda, 2016).

RESULTS AND DISCUSSION

Formulation and optimization of SLN

Selection of preparation of method

The microemulsion technique was selected as the method of choice in the formulation of solid lipid nanoparticles, because it showed better results in terms

of particle size, particle shape, drug entrapment etc. as compared to the other methods, as seen in Table I. The versatility and flexibility of this method allows for the use of different lipids and drug candidates. In the present study, the lipid glyceryl monostearate was used for the preparation of ERY-loaded SLNs.

TABLE I - Comparison between different methods used for the preparation of SLNs

Methods	Lipids	Particle Size (nm)
Solvent Evaporation Method	Stearic acid	1428
	GMS	998
	Comparitol ATO 888	1272
Microemulsion Technique	Stearic acid	391
	GMS	176.2
	Comparitol ATO 888	380.8
Solvent Emulsification Diffusion Technique	Stearic acid	642
	GMS	519
	Comparitol ATO 888	528

Optimization of formulation component

Screening of lipids for SLNs

Three lipids – stearic acid, glycerol monostearate, and Comparitol 888 – were used for the formation of SLNs. A drastic increase in the particle size and decrease in drug entrapment was observed with the use of Comparitol 888 and stearic acid. Among these lipids, glyceryl monostearate was selected for the development of SLNs as mentioned in Table II. GMS had the particle size within the nanoparticle range and the demonstrated maximum drug entrapment.

TABLE II - Screening of lipids for SLNs

Lipids	Particle Size (nm)	Poly dispersity Index (PDI)	Entrapment (%)
Stearic Acid	1391 ± 4.76	0.569 ± 0.06	48.24 ± 1.39
GMS	176.2 ± 0.48	0.275 ± 0.05	73.56 ± 0.28
Comparitol 888 ATO	380.8 ± 1.67	0.412 ± 0.02	57.29 ± 0.81

Optimization of drug lipid loading ratio

A drastic increase in the particle size and decrease in the drug entrapment was observed when the drug:

lipid ratio was increased from 1:1 to 1:5 w/w. The results indicate that the optimal drug lipid ratio is 1:2w/w, as depicted in Table III. The increase in particle size and decrease in drug entrapment was probably caused by the increase in lipid quantity, which resulted in drug expulsion due to the crystalline structure of lipid.

TABLE III - Optimization of drug lipid ratio

Drug Lipid Ratio	Particle Size (in nm)	Drug Entrapment (%)
1:1	159 ± 0.91	44.2 ± 0.36
1:2	176 ± 0.86	78.1 ± 0.74
1:3	476 ± 1.75	55.3 ± 1.03
1:4	508 ± 2.56	22.4 ± 0.55
1:5	719 ± 3.21	34.5 ± 0.87

Optimization of surfactant concentration

The concentration of the surfactant was optimized in order to obtain the smallest possible SLNs with maximum percentage of drug entrapment. The optimized one had 0.5% concentration of surfactant, as it lead to the smallest particle size, zeta potential within range, and it did not cause aggregation after 24 hours, as depicted in Table IV.

TABLE IV - Optimization of Surfactant Concentration

Surfactant Conc.	Particle Size (nm)	Zeta Potential (mV)	Aggregation (After 24 h)
0.5%	176 ± 1.87	24.42 ± 0.95	-
1.0%	213 ± 1.78	25.26 ± 1.02	-
1.5%	224 ± 2.12	24.12 ± 0.59	+
2.0%	278 ± 1.27	24.38 ± 1.01	+

Optimization of stirring time

During stirring, the organic solvent diffused into the aqueous phase, leading to the synthesis of SLNs. The speed and time of stirring may influence the particle size as well as the drug entrapment. Upon increasing the stirring time from 30 to 60 minutes, a decrease in particle size from 528 to 176 nm and an increase in entrapment i.e. 78.59% was observed (Table V).

Optimization of Sonication time

The sonication time was optimized by using the Bandlin Sonoplus by Biomate India, and 20 minutes of sonication was found to be the optimum time to reduce the particle size (Table VI).

TABLE V - Optimization of Stirring Time

Time (min.)	Particle Size (nm)	Drug Entrapment (%)
30	528 ± 3.29	59.94 ± 0.50
45	213 ± 2.25	64.73 ± 0.18
60	176 ± 1.73	78.59 ± 0.12

TABLE VI - Showing Optimization of Probe Sonication

Sonication time (min)	Particle size (nm)	Drug Loading
5	217.6 ± 1.78	59.94 ± 0.54
10	204.5 ± 2.16	63.23 ± 0.76
15	189.8 ± 1.09	68.92 ± 0.52
20	188.9 ± 1.42	72.79 ± 0.12

Design of experiment by Taguchi model

The Taguchi model was used for simultaneous optimization of all variables used in the design of various nine formulations (F1–F9). All these variables were used at three different levels. The results in terms of particle size, polydispersity index, zeta potential, and drug entrapment efficiency are tabulated in Table VIII. In Formulation F1 lump formation occurred after 24 hours, therefore, the batch was discarded. F4 led to the smallest particle size with the highest drug loading capacity, therefore this batch was used as the optimized formulation. The codes for all four variables at three different levels were shown in the Table VII. On the basis of particle size, batch 4 is taken as optimized, hence the optimized parameter was found to be A2B1C2D3 as shown in above mentioned Table VII.

Measurement particle size, zeta potential, and size distribution

The particle size of formulation was found in the range of 176.2 to 374 nm, as shown in Table VIII. Formulation factors like lipid amount and poloxamer

188 concentration were found to influence the particle size of the formulation significantly. Zeta potential (ZP) is the charge on a particle surface, and it is the inherent property of a particle. ZP plays a major role in the stability of multi-particulate liquid systems. It does not allow the particles to come in contact with each other and prevents aggregation thereby stabilizing the system. The ZP of glycerin monostreate-based SLN was found to be -34.0 indicating a stable formulation. PDI measures the particles size distribution in a system. This indicates the variation/dispersion in particle size in SLN dispersion. The PDI values of the developed SLNs were found to be less than 1, confirming monodisperse particles (Table VIII).

In vitro drug release studies from SLNs

As seen in Figure 2, F4 was selected as the optimized formulation. It was clear from all the formulations that there was an initial burst release ranging from 5.879% (F2) to 15.773% (F7). This was due to surface-absorbed drug on SLNs, which was followed by a sustained release, varying from 73.18% (F8) to 92.90% (F4) as shown in Figure 2. This is due to the drug slowly diffusing through the lipid core. Thus, the formulation F4 was optimized as it released 93% of the drug in 24 hours. It was revealed from the results that ERY-loaded SLNs showed a slow release at pH 6.4 with a sustained pattern of release.

Evaluation of ERY SLN-loaded gel formulation

ERY SLN gel prepared with Carbopol 940 was evaluated for crucial parameters as listed in Table VIII. The gel demonstrated the desired homogeneity and viscosity as well as high spreadability and extrudability for the formulation. The rheological behavior of gel systems was studied. In a gel system, the consistency depends on the ratio of solid fraction, which produces the structure of the liquid fraction. The viscosity of ERY-loaded SLNs gel was found to be 9563 ± 7.48 centipoises. The gel was found to be uniform with pourable viscosity.

TABLE VII - Showing codes for all variables at three different level

Variables	Levels		
	Low	Medium	High
Drug to lipid ratio	A1 (1:1)	A2 (1:2)	A3 (1:3)
Conc. of Surfactants	B1 (0.5%)	B2 (1%)	B3 (1.5%)
Stirring time (min.)	C1 (30 min)	C2 (45 min)	C3 (60 min)
Sonication time (min.)	D1 (10 min)	D2 (15 min)	D3 (20 min)

TABLE VIII - Codes for four variables at three different levels

Codes	Parameters				Particle Size (nm)	PDI	ZP (mV)	DL (%)	DE (%)
	A	B	C	D					
F1	1	1	1	1					
F2	1	2	2	2	256.6 ± 2.41	0.314 ± 0.008	24.26 ± 0.83	34.29	31.29
F3	1	3	3	3	274.7 ± 3.27	0.374 ± 0.012	20.71 ± 1.04	60.19	68.42
F4	2	1	2	3	176.2 ± 1.82	0.275 ± 0.011	-34.0 ± 0.84	69.73	73.56
F5	2	2	3	1	209.4 ± 2.48	0.496 ± 0.032	20.14 ± 0.86	59.37	71.97
F6	2	3	1	2	215.8 ± 3.23	0.472 ± 0.061	-23.94 ± 1.03	61.19	71.38
F7	3	1	3	2	374.3 ± 4.17	0.561 ± 0.005	-23.21 ± 1.05	58.21	52.73
F8	3	2	1	3	327.9 ± 3.20	0.673 ± 0.083	-25.25 ± 0.95	54.80	36.69
F9	3	3	2	1	319.2 ± 4.15	0.712 ± 0.023	-24.69 ± 1.10	54.96	38.14

TABLE IX - Evaluation of ERY loaded SLN gel

Clarity	Mean pH ± S.D. (n=3)	Homogeneity	Mean Viscosity (Pa.s) ± S.D. (n=3)	Mean spreadability (gcm/sec) ± S.D. (n=3)	Mean Extrudability (gm) ± S.D. (n=3)
++	6.5 ± 0.34	Good	9563 ± 7.48	19.51 ± 0.71	231 ± 4.65




FIGURE 1 - Particle size of optimized formulation (F4).




FIGURE 2 - In vitro release profile of developed SLNs.

In vitro release profile of gel

The *in vitro* release profile (Figure 3) of ERY plain

gel (2%w/w) and ERY SLN-loaded gel (2%w/w) are seen in Figure 3. The percentage of cumulative drug release of plain gel and ERY-loaded SLN gel were found to be 90.94% and 87.94% respectively after 24 hours. The release of ERY from SLN-loaded gel was found to be low as compared to plain gel. SLN gel showed slower and more sustained release as compared to ERY plain gel.




FIGURE 3 - In vitro release profile of developed Plain and SLN loaded gel.

The rate of the release of ERY SLN-loaded gel was studied by using various models. In the case of lipophilic matrices, swelling and erosion of polymers occurs simultaneously, and both contribute to the overall drug release rate. It was documented earlier that the drug release from lipophilic matrices shows a typical time-dependent

profile (i.e. decrease of drug release with time due to increased diffusion path). This inherent limitation leads to first order release kinetic.

In our study, the formulation was designed for the controlled release of ERY, which was evaluated by *in vitro* drug release. To study the release kinetic of the drug, the result of the *in vitro* drug release studies were plotted with various kinetic models like zero order, first order, Kosermeier and Peppas equation, and Higuchi's kinetics model. The regression values for the models used for ERY-SLN formulations are mentioned in Table X.

TABLE X - Drug release kinetics

Zero order	First order	Higuchi	Korsemeyer-Peppas
R ²	R ²	R ²	R ²
0.955	0.966	0.981	0.782

The result of the *in vitro* release study of SLN gel followed Higuchi kinetics ($R^2=0.981$). This correlates with the mechanism of drug release from a transdermal system. The Higuchi model was developed to depict the release of low soluble drugs when incorporated in semisolid and solid matrices (Bisht *et al.*, 2017).

In vitro antimicrobial activity

A comparative evaluation of zone of inhibition of the prepared ERY SLN-loaded gel and ERY plain gel is mentioned in Figure 4. The zone of inhibition of SLN-based gel was significantly higher as compared to plain gel. ERY-loaded SLNs gel can act as an effective therapeutic modality for treating acne by a decrease dose and frequency as well as improved patient compliance.




FIGURE 4 - Zone of inhibition by developed Plain and SLN loaded gel.

CONCLUSION

The ERY-loaded SLN gel was successfully incorporated into carbopol gel for topical delivery with a sustained release of drug. Carbopol 940 (2%w/v) gel was used as a hydrogel base with good spreadability and extrudability with compatible pH. The *in vitro* release profile of erythromycin-loaded SLN gel showed a sustained pattern of drug delivery, and thus it enhances antimicrobial activity after 30 hours when compared with ERY plain gel. The obtained results suggest that the developed formulation benefits from its nano size and promises better therapeutic efficacy. ERY SNL-loaded gel can therefore be a good replacement for the conventional formulation with benefits of decreased dose and dosing frequency as well as improved patient compliance.

ACKNOWLEDGEMENT

The authors are thankful to Department of Pharmaceutics, Jamia Hamdard University, New Delhi, India for providing the essential facilities needed in this research.

CONFLICT OF INTEREST STATEMENT

The authors report no conflict of interest in this work. The author is responsible for content and the writing of the paper.

REFERENCES

- Ahlin P, Kristl J, Kobar S. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in the dispersion. *Acta Pharm.* 1998;48:257-67.
- Anwer MK, Al-Mansoor MA, Jamil S, Al-Shdefat R, Ansari MN, Shakeel F. Development and evaluation of PLGA polymer-based nanoparticles of quercetin. *Int J Biol Macromol.* 2016a;92:213-9.
- Anwer MK, Jamil S, Ansari MJ, Iqbal M, Imam F, Shakeel F. Development and evaluation of Olmesartan medoxomil-loaded PLGA nanoparticles. *Mat Res Innovat.* 2016b;20(3):193-97.
- Balouiri M, Sadiki M, Ibensouda SK. Methods for *in vitro* evaluating antimicrobial activity: A review. *J Pharm Anal.* 2016;6(2):71-9.

- Bhadra S, Prajapati AB, Bhadra D. Development of pH sensitive polymeric nanoparticles of erythromycin stearate. *J Pharm Bio Allied Sci.* 2016;8(2):135-40.
- Bisht D, Verma D, Mirza MA, Anwer MK, Iqbal Z. Development of ethosomal gel of ranolazine for improved topical delivery: In vitro and ex vivo evaluation. *J Mol Liquids.* 2017;225:475-81.
- Ekambaram P, Sathali AH, Priyanka K. Solid lipid nanoparticles: A review. *Scient Rev Chem Comm.* 2012;2(1):80-102.
- Helgason T, Awad TS, Kristbergsson K, Me Clements DJ, Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). *J Colloid Interface Sci.* 2009;334(1):75-81.
- Loxley A. Solid lipid nanoparticles for the delivery of pharmaceutical actives. *Drug Deliv Technol.* 2009;9(8):32.
- Manjunath K, Venkateswarlu V. Preparation, characterization, and in vitro release kinetics of clozapine solid lipid nanoparticles. *J Control Release.* 2004;95(3):627-38.
- Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization, and applications. *Adv Drug Deliv Rev.* 2001;47(2-3):165-96.
- Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: A review on formulation technology, types, and applications toward targeted drug delivery. *Nanomed Nano technol Biol Med.* 2010;6(1):e9-e24.
- Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: A review of the state of the art. *Eur J Pharm Bio pharm.* 2000;50:161-77.
- Mutimer MN, Riffkin C, Hill JA, Glickman ME, Cyr GN. Modern ointment bases technology II: Comparative evaluation of bases. *J Am Pharm Assoc.* 1956;45(4):212-18.
- Nazzal S, Khan M. Response surface methodology for the optimization of ubiquinone self-nanoemulsifying drug delivery system. *AAPS Pharm Sci Tech.* 2002;3(1):23-31.
- Nadkar S, Lokhande C. Current trends in novel drug delivery: An OTC perspective. *Pharma Time.* 2010;42(4):17-23.
- Surender V, Deepika M. Solid lipid nanoparticles: A comprehensive review. *J Chem Pharm Res.* 2016;8(8):102-14.
- Taguchi G. *System of Experimental Design.* New York: UNIPUB, Kraus International Publications; 1987.
- Yassin AB, Anwer MK, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA. Optimization of 5-fluorouracil solid-lipid nanoparticles: A preliminary study to treat colon cancer. *Int J Med Sci.* 2010;7(6):398-408.

Received for publication on 03th July 2017

Accepted for publication on 21st June 2018